Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Prosciento Inc

Neither a doctor nor a teaching hospital

Research payments

$12,298,289

221 payments

Through program year 2025, Prosciento Inc is reported as receiving $12,298,289 in research payments, across 221 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,499,272 99
2024 Research $3,758,909 32
2023 Research $84,340 2
2022 Research $1,012,075 16
2021 Research $1,405,364 29
2020 Research $592,041 21
2019 Research $946,287 22

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $5,503,018 76 payments
  2. Dexcom, Inc. $2,078,344 46 payments
  3. Amgen Inc. $1,738,687 3 payments
  4. Pfizer Inc. $972,600 21 payments
  5. Regeneron Pharmaceuticals, Inc. $625,575 50 payments
  6. AstraZeneca UK Limited $468,098 6 payments
  7. AstraZeneca Pharmaceuticals LP $456,991 6 payments
  8. Alkermes, Inc. $377,383 11 payments
  9. Genentech, Inc. $77,593 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2A, Single Dose, Open-Label, Dose-Exploration Study to Assess $5,503,018 76 payments
  2. A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and ?-cell Function in Participants With Type 2 Diabetes Mellitus $1,383,659 1 payment
  3. Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System - (G7 Pivotal) $803,038 8 payments
  4. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity $582,701 45 payments
  5. A Phase 2A Randomized Double Blind Sponsoropen Placebo Controlled Parallel Group Study to Assess the Pharmacodynamics Safety and Tolerability of Pf05221304 and Pf06865571 Coadministered for 6 Weeks in Adults With Nonalcoholic Fatty Liver Disease Nafld $546,113 16 payments
  6. Feasibility Study of the Dexcom G7 Continuous Glucose Monitoring (CGM) Delta Sensor (Delta Oh3) $483,780 7 payments
  7. AZD2693, Cardiovascular, Renal and Metabolism $468,098 6 payments
  8. Human Pulse Labeling Study to Assess Synthesis and Secretion of Proteins $393,572 3 payments
  9. Feasibility Study Evaluating the Performance of Modified Dexcom Continuous Glucose Monitoring (CGM) System in Adults With Diabetes Mellitus $380,371 11 payments
  10. A Randomized, Double-Blind, Parallel-Group Study in Healthy Subjects to Characterize Insulin Sensitivity and Lipid Metabolism in Response to Treatment with ALKS 3831 and Olanzapine $377,383 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record